CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Text Block [Abstract]
Sales revenue	$ 1,171,698	$ 717,229	$ 2,082,374	$ 2,032,513
Cost of goods sold	(1,857,150)	(302,744)	(2,481,519)	(883,309)
Gross profit (loss)	(685,452)	414,485	(399,145)	1,149,204
General and administrative expenses	1,403,314	3,806,320	3,468,863	7,623,356
LOSS FROM OPERATIONS	(2,088,766)	(3,391,835)	(3,868,008)	(6,474,152)
OTHER INCOME (EXPENSE)
Interest expense	(475,558)	(2,765,866)	(913,374)	(4,422,714)
Other income/(expense)	69,457	(3,047,667)	69,457	(2,949,806)
Total other expense	(406,101)	(5,813,533)	(843,917)	(7,372,520)
NET LOSS BEFORE INCOME TAXES	(2,494,867)	(9,205,368)	(4,711,925)	(13,846,672)
Income tax benefit	57,392	0	0	0
LOSS FROM CONTINUING OPERATIONS	(2,437,475)	(9,205,368)	(4,711,925)	(13,846,672)
Loss on discontinued operations	(491,131)	(825,697)	(755,565)	(1,535,876)
NET LOSS	(2,928,606)	(10,031,065)	(5,467,490)	(15,382,548)
Net loss attributable to non-controlling interest	(245,565)	(291,416)	(377,781)	(475,559)
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.	(2,683,041)	(9,739,649)	(5,089,709)	(14,906,989)
Net loss attributable to common stockholders of GB Sciences, Inc.
Net loss	$ (2,683,041)	$ (9,739,649)	$ (5,089,709)	$ (14,906,989)
Net loss per common share - basic and diluted
Continuing operations	$ (0.01)	$ (0.05)	$ (0.02)	$ (0.07)
Discontinued operations	.00	.00	.00	(0.01)
Net loss per share - basic and diluted	$ (0.01)	$ (0.05)	$ (0.02)	$ (0.08)
Weighted average common shares outstanding - basic and diluted	252,700,538	204,143,491	248,392,203	189,787,747